RxDoctor Payments Data

Eric Holt, MD

Internal Medicine · Meridian, MSNPI 1013070424

Payments from drug & device makers

$3,164in general payments, 2019–2025

Across 104 payments — averaging $30.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$929
  • Bayer$639
  • Novartis$282
  • Boehringer Ingelheim$220
  • Vifor Pharma, Inc.$165
  • Travere Therapeutics, Inc.$164
  • plus $766 from 12 others

What the payments were for

  • Food & beverage$3,14099%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,164 in reported general payments places this provider in the 80th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$164,849
Medicare patients
246
Services billed
1,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl37$131,728
VelphoroSucroferric Oxyhydroxide53$128,249
AuryxiaFerric Citrate41$75,316
FarxigaDapagliflozin Propanediol74$54,769
Sevelamer Carbonate203$41,833
KerendiaFinerenone39$32,556
JardianceEmpagliflozin31$18,763
Lanthanum Carbonate15$8,838
Novolog FlexpenInsulin Aspart12$1,597
Nebivolol Hcl14$855
Hydralazine Hcl53$594
Nifedipine ErNifedipine20$378
Amlodipine Besylate83$294
Losartan Potassium39$287
Potassium Chloride12$274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$97$75,31641 claims
AstraZenecaFarxiga$929$54,76974 claims
BayerKerendia$639$32,55639 claims
Boehringer IngelheimJardiance$220$18,76331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Meridian

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →